Weekly Aspergillosis Research Update: Week ending 27 April 2026

Highlights this week

Occupational non-invasive aspergillosis

A French national multicentre study reviewed occupational cases of non-invasive aspergillosis over more than 20 years.

Why it matters: workplace exposure (dust, compost, damp buildings, waste handling) may contribute to disease in some patients and should be considered in clinical history-taking.

Reference: Michel A et al.

PMID: 42033338

Tezepelumab in allergic bronchopulmonary aspergillosis

A small 4-patient case series explored the use of tezepelumab in allergic bronchopulmonary aspergillosis (ABPA) with severe asthma.

Why it matters: adds to growing interest in biologics for ABPA, particularly where steroid burden is high. Evidence remains early and limited.

Reference: Sanz-Sanjosé B et al.

PMID: 42017435

Mucus plugging in chronic lung disease

A narrative review examined mucus plugging in chronic obstructive lung diseases and bronchiectasis, including ABPA.

Why it matters: mucus plugs can block airways, worsen breathlessness, and contribute to infection risk and scan abnormalities.

Reference: Schou C et al.

PMCID: PMC13103984

Invasive aspergillosis treatment

A systematic review and network meta-analysis compared antifungal treatment regimens for invasive aspergillosis.

Why it matters: invasive aspergillosis remains a high-mortality infection; early diagnosis and optimal antifungal therapy are critical. Triazoles and other antifungals remain central to management. :contentReference{index=0}

Reference: Gu Q et al.

PMID: 42012594

Natural killer cells and resistant Aspergillus

A laboratory study demonstrated antifungal activity of human natural killer cells against azole-resistant Aspergillus fumigatus.

Why it matters: improves understanding of immune defence mechanisms and may inform future therapies.

Reference: Namie H et al.

PMID: 42012259

Antifungal susceptibility surveillance

A multicentre Taiwan study examined susceptibility patterns of clinical Aspergillus isolates (2021–2023).

Why it matters: resistance patterns vary geographically, influencing antifungal treatment choices.

Reference: Hsieh M et al.

PMID: 42012212

Invasive aspergillosis in severe viral illness

A study explored invasive pulmonary aspergillosis complicating severe fever with thrombocytopenia syndrome.

Why it matters: reinforces the link between severe illness, immune disruption, and risk of invasive aspergillosis.

Reference: Du Q et al.

PMID: 42032512

Lower-priority or indirect papers

Veterinary study (canine nasal aspergillosis)

Primarily a veterinary oncology study with limited relevance to human disease.

Reference:

PMID: 42007656

Canakinumab pharmacovigilance

Focuses on drug safety rather than aspergillosis.

Reference:

PMID: 41998856

Overall message

This week’s research highlights the wide scope of aspergillosis—from environmental and occupational exposure to allergic disease, invasive infection, antifungal resistance, and immune responses. The most relevant developments for patients remain ABPA biologics, mucus plugging, and antifungal resistance trends.

Path: Start » Weekly Updates » Weekly Aspergillosis Research Update: Week ending 27 April 2026